High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from "orphan drug" to a standard-of-care?

Leuk Lymphoma. 2016;57(1):1-3. doi: 10.3109/10428194.2015.1058937. Epub 2015 Jul 7.

Authors

Carrie van der Weyden¹, H Miles Prince^{1

2}

Affiliations

¹ a Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne , Victoria , Australia.
² b Division of Cancer Medicine, Peter MacCallum Cancer Centre and University of Melbourne , Melbourne, Victoria , Australia.

PMID: 26059059
DOI: 10.3109/10428194.2015.1058937

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Central Nervous System Neoplasms / drug therapy
Humans
Lymphoma / drug therapy
Nervous System
Orphan Drug Production*
Thiotepa / therapeutic use*
Transplantation Conditioning

Substances

Thiotepa